Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With Metastatic Breast Cancer (mBCA) Who Have Progressed Through Prior Hormonal Therapy
Conditions
Interventions
Imprime PGG
Pembrolizumab
Locations
16
United States
The University of Arizona Cancer Center - North Campus
Tucson, Arizona, United States
The University of Arizona Cancer Center
Tucson, Arizona, United States
University of Colorado at Denver
Denver, Colorado, United States
University of Miami and Clinics -Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Mt. Sinai (Miami)
Miami Beach, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Start Date
November 9, 2021
Primary Completion Date
March 22, 2023
Completion Date
April 12, 2023
Last Updated
June 22, 2023
NCT07067138
NCT06878248
NCT04669873
NCT03162627
NCT03165487
NCT02204098
Lead Sponsor
HiberCell, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions